Skip to main content
. 2011 May 17;6(5):e19542. doi: 10.1371/journal.pone.0019542

Figure 6. Systemic IRBP-specific immune responses in each group.

Figure 6

IRBP-specific lymphocyte proliferation (A) and IL-17 production in vitro (B) show no significant difference among lower dose of AAV2.hIFN-α, PBS and AAV2.GFP treated mice (P>0.05). A significant decline of lymphocyte proliferation is observed in higher dose of AAV2.hIFN-α treated mice compared with PBS injected (p = 0.012), AAV2.GFP injected (p = 0.019) and lower dose of AAV2.hIFN-α treated mice (p = 0.027). Similarly, the IL-17 production is significantly downregulated in higher dose of AAV2.hIFN-α treated mice as compared with PBS injected (p = 0.025), AAV2.GFP injected (p = 0.013) and lower dose of AAV2.hIFN-α treated mice (p = 0.018). Results are presented as mean ± standard deviation and every experiment was performed three times.